ScholarIQanswers from OpenAlex

The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target

PaperCitations, authors & open-access status

The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target is a paper indexed in ScholarIQ from OpenAlex.

How many citations does The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target have?

ScholarIQcitation count

The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target has 56 citations in the OpenAlex counts ScholarIQ stores.

When was The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target published?

ScholarIQyear

The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target has 2022 year in the ScholarIQ index.

What is the open-access status of The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target?

ScholarIQoa status

The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target has gold oa status in the ScholarIQ index.

What is the DOI of The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target?

ScholarIQdoi

The DOI for The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target is on the source record.

What is the PMID of The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target?

ScholarIQpmid

The PMID for The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target is on the source record.

What is the OpenAlex record for The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target?

ScholarIQopenalex

The OpenAlex for The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial